Moreover, ABT‐122, a dual TNF/IL‐17A inhibitor, demonstrated favorable safety and reductions in inflammatory biomarkers in a phase I trial involving RA patients on stable methotrexate treatment [528]. This evidence concerns the gene IL17A and rheumatoid arthritis.